Calgary, Alberta, August 19, 2008– Orcrist Bio Inc., a biotech company developing stem cell-mobilizing pharmaceuticals, has co-authored a peer reviewed publication with Medistem Inc. (OTC BB: MEDS.OB), and collaborators at six academic institutions, pro Readmore
Calgary, Alberta, May 21, 2008– Orcrist Bio Inc. (ORC) and Medistem Laboratories, Inc. (OTCB:MDSM.OB - News) announced today that the companies have entered into a collaborative agreement to co-develop therapies based upon their respective core intellec Readmore
Calgary, Alberta, May 9, 2008– Orcrist Bio Inc. today announced that it has entered into a Royalty and Assignment Agreement with BioMS Medical Corp (TSX:MS) for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic use Readmore
About Us
Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists.
Our lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related white blood cell depletion. We are actively looking to add to our pipeline through in-licensing opportunities.
Orcrist is located in Calgary, Alberta. The Company is financed by its founders and by private investors.
Calgary, Alberta, August 19, 2008 – Orcrist Bio Inc., a biotech company developing stem cell-mobilizing pharmaceuticals, has co-authored a peer reviewed publication with Medistem Inc. (OTC BB: MEDS.OB), and collaborators at six academic institutions, pro 
